Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
2021 · Clinical Cancer Research · 61 citations
https://doi.org/10.1158/1078-0432.ccr-20-3017
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
230
Citations
3
h-index
3
i10-index
Stephen M. Scott is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer Mechanisms and Therapy & Nuclear Receptors and Signaling & HER2/EGFR in Cancer Research. The author has an h-index of 3, co-authored 33 publications.
https://doi.org/10.1158/1078-0432.ccr-20-3017
https://doi.org/10.1158/1078-0432.ccr-24-1948
Click to start Chat